Literature DB >> 20652228

Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.

N Sugiya1, A Nakashima, N Takasugi, A Kawai, K Kiribayashi, J Tanaka, N Kohno, N Yorioka.   

Abstract

SUMMARY: Postmenopausal hemodialysis patients are at risk of complications related to renal mineral and bone disorder, and postmenopausal osteoporosis. In 112 postmenopausal hemodialysis patients, free estrogen index was positively correlated with bone mineral density (BMD) Z-score and the annual percent change of BMD in multiple regression analysis. Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.
INTRODUCTION: Women on dialysis are not only at risk of developing mineral and bone disorder, but also suffer from postmenopausal osteoporosis. We assessed the effect of sex hormones on bone metabolism in postmenopausal hemodialysis patients.
METHODS: We enrolled 112 postmenopausal hemodialysis patients with a mean age of 68.4 ± 10.4 years. We measured the serum levels of estradiol, testosterone, sex hormone-binding globulin (SHBG), and intact parathyroid hormone (intact-PTH), as well as bone metabolism parameters and radial bone mineral density (BMD). The free estrogen index (FEI) was calculated from the estradiol and SHBG values. After conventional dialysis was performed for 12 months, BMD was measured again and the annual percent change was calculated. Estradiol and SHBG were also measured in 25 postmenopausal women without chronic kidney disease.
RESULTS: Estradiol levels were higher in the hemodialysis patients than in the postmenopausal women without chronic kidney disease. In patients with relatively normal bone turnover (intact-PTH: from 150 to 300 pg/ml), the FEI showed a positive correlation with the BMD Z-score. The annual percent change of BMD showed a positive correlation with the FEI according to multiple regression analysis.
CONCLUSIONS: Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652228     DOI: 10.1007/s00198-010-1350-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  30 in total

1.  Endogenous sex hormones and glucose tolerance status in postmenopausal women.

Authors:  Sherita Hill Golden; Adrian S Dobs; Dhananjay Vaidya; Moyses Szklo; Susan Gapstur; Peter Kopp; Kiang Liu; Pamela Ouyang
Journal:  J Clin Endocrinol Metab       Date:  2007-01-23       Impact factor: 5.958

2.  Effects of estradiol and progesterone on parathyroid hormone secretion from human parathyroid tissue.

Authors:  B Duarte; G K Hargis; S C Kukreja
Journal:  J Clin Endocrinol Metab       Date:  1988-03       Impact factor: 5.958

3.  Gynecologic and reproductive issues in women on dialysis.

Authors:  J L Holley; R J Schmidt; F H Bender; F Dumler; M Schiff
Journal:  Am J Kidney Dis       Date:  1997-05       Impact factor: 8.860

4.  Women's health issues in a dialysis population.

Authors:  H Rush; J Neugarten; M Coco
Journal:  Clin Nephrol       Date:  2000-12       Impact factor: 0.975

5.  Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women.

Authors:  J R Weisinger; L Gonzalez; H Alvarez; E Hernandez; R G Carlini; F Capriles; M Cerviño; R Martinis; V Paz-Martínez; E Bellorín-Font
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

6.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

7.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

8.  Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice.

Authors:  R Kitazawa; R B Kimble; J L Vannice; V T Kung; R Pacifici
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

9.  Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release.

Authors:  R Pacifici; L Rifas; R McCracken; I Vered; C McMurtry; L V Avioli; W A Peck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

10.  The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance.

Authors:  Paloma Alonso-Magdalena; Sumiko Morimoto; Cristina Ripoll; Esther Fuentes; Angel Nadal
Journal:  Environ Health Perspect       Date:  2006-01       Impact factor: 9.031

View more
  6 in total

1.  Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis.

Authors:  Jasna Aleksova; Alexander J Rodriguez; Robert McLachlan; Peter Kerr; Frances Milat; Peter R Ebeling
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 2.  Traditional and Non-traditional Risk Factors for Osteoporosis in CKD.

Authors:  Hanne Skou Jørgensen; Karel David; Syazrah Salam; Pieter Evenepoel
Journal:  Calcif Tissue Int       Date:  2021-02-14       Impact factor: 4.333

3.  Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients.

Authors:  Mehmet Tanrisev; Gulay Asci; Ozkan Gungor; Fatih Kircelli; Ebru Sevinc Ok; Mumtaz Yilmaz; Osman Z Sahin; Kezban Pinar Ozen; Gultekin Suleymanlar; Huseyin Toz; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2012-04-18       Impact factor: 2.370

4.  Liuwei Dihuang Pill () Treats Postmenopausal Osteoporosis with Shen (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator of Transcription Signal Pathway by Up-regulating Cardiotrophin-Like Cytokine Factor 1 Expression.

Authors:  Ji-Rong Ge; Li-Hua Xie; Juan Chen; Sheng-Qiang Li; Hui-Juan Xu; Yu-Lian Lai; Long-Long Qiu; Chen-Bo Ni
Journal:  Chin J Integr Med       Date:  2016-12-27       Impact factor: 1.978

5.  Bioavailable Testosterone Is Positively Associated With Bone Mineral Density in Male Kidney Transplantation Candidates.

Authors:  Hanne Skou Jørgensen; Simon Winther; Morten Bøttcher; Ellen-Margrethe Hauge; Lars Rejnmark; My Svensson; Per Ivarsen
Journal:  Kidney Int Rep       Date:  2018-02-02

6.  Articular cartilage chondrocytes express aromatase and use enzymes involved in estrogen metabolism.

Authors:  Martin Schicht; Jana Ernst; Andrea Nielitz; Lars Fester; Michael Tsokos; Saskia S Guddat; Lars Bräuer; Judith Bechmann; Karl-Stefan Delank; David Wohlrab; Friedrich Paulsen; Horst Claassen
Journal:  Arthritis Res Ther       Date:  2014-04-11       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.